Eterna Therapeutics Inc
ERNA
View Detailed Chart
0.191USD
-0.017-8.36%
Market hours （ET）Quotes delayed by 15 min
6.77KMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-8.36%
5 Days
-28.19%
1 Month
-33.08%
6 Months
-83.69%
Year to Date
-84.10%
1 Year
-92.71%
View Detailed Chart
TradingKey Stock Score of Eterna Therapeutics Inc
Currency: USD Updated: 2026-03-27Key Insights
Eterna Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 221 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Eterna Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Eterna Therapeutics Inc Highlights
StrengthsRisks
Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
Undervalued
The company’s latest PE is -0.09, at a low 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 35.92K shares of this stock.
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Eterna Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Eterna Therapeutics Inc Info
Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
Ticker SymbolERNA
CompanyEterna Therapeutics Inc
CEOLuther (Sanjeev)
Websitehttps://www.ernexatx.com/
Related Instruments
-0.69%
-0.70%
+0.91%
+3.22%
+0.24%
+0.65%
+0.28%
-0.77%
+0.43%
-0.74%
+1.86%
-0.27%
+0.87%
+0.23%
-2.68%
0.00%
+0.73%
-0.37%
+1.73%
-1.80%Popular Symbols
247.435
-5.455 (-2.16%)
167.060
-0.460 (-0.27%)
67499.510
+915.460 (+1.38%)
260.600
-14.740 (-5.35%)
2061.630
+61.630 (+3.08%)
362.565
+0.735 (+0.20%)
4538.010
+45.490 (+1.01%)
101.172
+0.563 (+0.56%)
1.147
-0.004 (-0.33%)
159.520
-0.732 (-0.46%)
